{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:44Z","timestamp":1787027804720,"version":"build-2736575974"},"reference-count":48,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T00:00:00Z","timestamp":1766275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives. Prostate cancer (PCa) is the second leading cause of cancer-related mortality among men in the United States. Treatment with second-generation androgen receptor (AR) inhibitors, such as enzalutamide, can trigger lineage plasticity, promoting the transdifferentiation of PCa cells into an AR-independent, poorly differentiated neuroendocrine phenotype (NEPC). The receptor tyrosine kinase EPHA3 is a critical driver for NEPC. It is overexpressed in PCa, particularly in androgen-independent and neuroendocrine subtypes. EPHA3 activates c-Myc signaling to enhance EZH2 expression, promoting histone H3K27 trimethylation. The neural transcription factor BRN2 functions upstream of both EZH2 and ASCL1. The latter regulates the Notch pathway ligand DLL3, thereby orchestrating neuroendocrine differentiation. Elevated expression of classical neuroendocrine markers CHGA and SYP is characteristic of the NEPC phenotype. This study reports the novel usage of the olive phenolic S-(-)-hydroxyoleocanthal (HOC, oleacein) to effectively control NEPC by targeting the EPHA3\u2013BRN2\u2013EZH2\u2013ASCL1\u2013DLL3\u2013SYP\u2013CHGA oncogenic network. Methods. Cell viability assays were conducted to assess in vitro effects. To model NEPC progression and recurrence, NCI-H660-Luc cells were xenografted into male athymic nude mice. RNA-sequencing was performed to compare the differentially expressed genes between placebo control and treated tumors. Results. HOC significantly attenuated the proliferation of NEPC NCI-H660 cells in vitro. Daily oral administration of HOC at 10 mg\/kg body weight markedly suppressed the progression of NEPC NCI-H660-Luc tumors. Continued HOC treatments after surgical excision of the primary tumors substantially reduced locoregional recurrence. HOC significantly downregulated the expression of EPHA3, BRN2, EZH2, ASCL1, DLL3, SYP, and CHGA in treated primary and recurrence tumors versus placebo control. Conclusions. These findings establish HOC as a multifaceted therapeutic entity capable of disrupting key NEPC oncogenic networks, highlighting its potential as a novel lead intervention for aggressive NEPC.<\/jats:p>","DOI":"10.3390\/cancers18010026","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T08:35:27Z","timestamp":1766392527000},"page":"26","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Olive Phenolic S-(-)-Hydroxyoleocanthal Attenuates Neuroendocrine Prostate Cancer via Modulation of EPHA3-Centered Oncogenic Network"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4223-3432","authenticated-orcid":false,"given":"Md Towhidul Islam","family":"Tarun","sequence":"first","affiliation":[{"name":"School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9057-4582","authenticated-orcid":false,"given":"Hassan Y.","family":"Ebrahim","sequence":"additional","affiliation":[{"name":"School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA"},{"name":"Department of Biomedical Sciences, Discipline of Pharmacology, Edward Via College of Osteopathic Medicine, Monroe, LA 71201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1456-4064","authenticated-orcid":false,"given":"Khalid A.","family":"El Sayed","sequence":"additional","affiliation":[{"name":"School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,21]]},"reference":[{"key":"ref_1","first-page":"485","article-title":"Prostate cancer statistics, 2025","volume":"75","author":"Kratzer","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Li, C., Cheng, D., and Li, P. (2025). Androgen receptor dynamics in prostate cancer: From disease progression to treatment resistance. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1542811"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/bco2.212","article-title":"Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta-analysis","volume":"4","author":"Chen","year":"2023","journal-title":"BJUI Compass"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kim, S.H., Kang, B.C., Seong, D., Lee, W.H., An, J.H., Je, H.U., Cha, H.J., Chang, H.W., Kim, S.Y., and Kim, S.W. (2021). EPHA3 contributes to epigenetic suppression of PTEN in radioresistant head and neck cancer. Biomolecules, 11.","DOI":"10.3390\/biom11040599"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Anderton, M., van der Meulen, E., Blumenthal, M.J., and Sch\u00e4fer, G. (2021). The role of the Eph receptor family in tumorigenesis. Cancers, 13.","DOI":"10.3390\/cancers13020206"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e22871","DOI":"10.1002\/jcla.22871","article-title":"The prognostic value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy","volume":"33","author":"Duan","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.canlet.2007.09.018","article-title":"Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells","volume":"259","author":"Singh","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.1007\/s11033-020-05571-8","article-title":"Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics","volume":"47","author":"London","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"104524","DOI":"10.1016\/j.critrevonc.2024.104524","article-title":"DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review","volume":"204","author":"Peddio","year":"2024","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2203820119","DOI":"10.1073\/pnas.2203820119","article-title":"Delta-like ligand 3\u2013targeted radioimmunotherapy for neuroendocrine prostate cancer","volume":"119","author":"Korsen","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-25-1211","article-title":"Safety and efficacy of Tarlatamab in patients with neuroendocrine prostate cancer: Results from the Phase 1b DeLLpro-300 study","volume":"31","author":"Aggarwal","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1158\/0008-5472.CAN-24-1388","article-title":"Neuroendocrine differentiation in prostate cancer requires ASCL1","volume":"84","author":"Rodarte","year":"2024","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1038\/s41467-024-51156-5","article-title":"Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes","volume":"15","author":"Venkadakrishnan","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1038\/s41467-022-29963-5","article-title":"ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer","volume":"13","author":"Nouruzi","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","article-title":"The master neural transcription factor BRN2 is an androgen receptor\u2013suppressed driver of neuroendocrine differentiation in prostate cancer","volume":"7","author":"Bishop","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/pin.12042","article-title":"POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer","volume":"63","author":"Ishii","year":"2013","journal-title":"Pathol. Int."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Sreekumar, A., and Saini, S. (2023). Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancer. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1075707"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/iju.13526","article-title":"Clinical and molecular features of treatment-related neuroendocrine prostate cancer","volume":"25","author":"Akamatsu","year":"2018","journal-title":"Int. J. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Thaper, D., Vahid, S., and Zoubeidi, A. (2020). Neural transcription factors in disease progression. Prostate Cancer: Cellular and Genetic Mechanisms of Disease Development and Progression, Springer.","DOI":"10.1007\/978-3-030-32656-2_19"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mentella, M.C., Scaldaferri, F., Ricci, C., Gasbarrini, A., and Miggiano, G.A. (2019). Cancer and Mediterranean diet: A review. Nutrients, 11.","DOI":"10.3390\/nu11092059"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1080\/10408398.2019.1650715","article-title":"Health-promoting properties of oleocanthal and oleacein: Two secoiridoids from extra-virgin olive oil","volume":"60","year":"2020","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Siddique, A.B., Ayoub, N.M., Tajmim, A., Meyer, S.A., Hill, R.A., and El Sayed, K.A. (2019). (\u2212)-Oleocanthal prevents breast cancer locoregional recurrence after primary tumor surgical excision and neoadjuvant targeted therapy in orthotopic nude mouse models. Cancers, 11.","DOI":"10.3390\/cancers11050637"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Siddique, A.B., Ebrahim, H.Y., Tajmim, A., King, J.A., Abdelwahed, K.S., Abd Elmageed, Z.Y., and El Sayed, K.A. (2022). Oleocanthal attenuates metastatic castration-resistant prostate cancer progression and recurrence by targeting SMYD2. Cancers, 14.","DOI":"10.3390\/cancers14143542"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Tarun, M.T., Elsayed, H.E., Ebrahim, H.Y., and El Sayed, K.A. (2025). The olive oil phenolic S-(\u2212)-oleocanthal suppresses colorectal cancer progression and recurrence by modulating SMYD2\u2013EZH2 and c-MET activation. Nutrients, 17.","DOI":"10.3390\/nu17030397"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pacifico, S., Bl\u00e1ha, P., Faramarzi, S., Fede, F., Michali\u010dkov\u00e1, K., Piccolella, S., Ricciardi, V., and Manti, L. (2022). Differential radiomodulating action of Olea europaea L. cv. Caiazzana leaf extract on human normal and cancer cells: A joint chemical and radiobiological approach. Antioxidants, 11.","DOI":"10.3390\/antiox11081603"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Carpi, S., Polini, B., Manera, C., Digiacomo, M., Salsano, J.E., Macchia, M., Scoditti, E., and Nieri, P. (2020). miRNA modulation and antitumor activity by the extra-virgin olive oil polyphenol oleacein in human melanoma cells. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.574317"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1039\/D0FO00089B","article-title":"Oleacein inhibits STAT3, activates the apoptotic machinery, and exerts anti-metastatic effects in SH-SY5Y human neuroblastoma cells","volume":"11","author":"Cirmi","year":"2020","journal-title":"Food Funct."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"21057","DOI":"10.18632\/aging.202154","article-title":"Mimetics of extra virgin olive oil phenols with anti-cancer stem cell activity","volume":"12","author":"Gumuzio","year":"2020","journal-title":"Aging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"115234","DOI":"10.1016\/j.biopha.2023.115234","article-title":"Anti-angiogenic effects of oleacein and oleocanthal: New bioactivities of compounds from extra virgin olive oil","volume":"165","author":"Marrero","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Siddique, A.B., Ebrahim, H., Mohyeldin, M., Qusa, M., Batarseh, Y., Fayyad, A., Tajmim, A., Nazzal, S., Kaddoumi, A., and El Sayed, K. (2019). Novel liquid\u2013liquid extraction and self-emulsion methods for simplified isolation of extra-virgin olive oil phenolics with emphasis on (\u2212)-oleocanthal and its oral anti-breast cancer activity. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214798"},{"key":"ref_32","unstructured":"Andrews, S. (2025, March 10). FastQC: A Quality Control Tool for High Throughput Sequence Data. Available online: https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: Ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: An efficient general-purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: A practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e742","DOI":"10.1002\/cpz1.742","article-title":"Preclinical models of neuroendocrine prostate cancer","volume":"3","author":"Cacciatore","year":"2023","journal-title":"Curr. Protoc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"66878","DOI":"10.18632\/oncotarget.19916","article-title":"Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and humans","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.lfs.2015.10.025","article-title":"Men and mice: Relating their ages","volume":"152","author":"Dutta","year":"2016","journal-title":"Life Sci."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Maylin, Z.R., Smith, C., Classen, A., Asim, M., Pandha, H., and Wang, Y. (2024). Therapeutic exploitation of neuroendocrine transdifferentiation drivers in prostate cancer. Cells, 13.","DOI":"10.3390\/cells13231999"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1038\/s41467-021-26042-z","article-title":"Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer","volume":"12","author":"Cejas","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Yerena, A., P\u00e9rez, M., Vallverd\u00fa-Queralt, A., Miliarakis, E., Lamuela-Ravent\u00f3s, R.M., and Escribano-Ferrer, E. (2021). Oleacein intestinal permeation and metabolism in rats using an in-situ perfusion technique. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13050719"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Yerena, A., Vallverd\u00fa-Queralt, A., Lamuela-Ravent\u00f3s, R.M., and Escribano-Ferrer, E. (2021). LC-ESI-LTQ-Orbitrap-MS for profiling the distribution of oleacein and its metabolites in rat tissues. Antioxidants, 10.","DOI":"10.3390\/antiox10071083"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Nikou, T., Sakavitsi, M.E., Kalampokis, E., and Halabalaki, M. (2022). Metabolism and bioavailability of olive bioactive constituents based on in vitro, in vivo and human studies. Nutrients, 14.","DOI":"10.3390\/nu14183773"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Lepore, S.M., Maggisano, V., Bulotta, S., Mignogna, C., Arcidiacono, B., Procopio, A., Brunetti, A., Russo, D., and Celano, M. (2019). Oleacein prevents high fat diet-induced adiposity and ameliorates some biochemical parameters of insulin sensitivity in mice. Nutrients, 11.","DOI":"10.3390\/nu11081829"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Lombardo, G.E., Lepore, S.M., Morittu, V.M., Arcidiacono, B., Colica, C., Procopio, A., Maggisano, V., Bulotta, S., Costa, N., and Mignogna, C. (2018). Effects of oleacein on high-fat diet-dependent steatosis, weight gain, and insulin resistance in mice. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00116"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/1\/26\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T08:42:34Z","timestamp":1766392954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/1\/26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,21]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18010026"],"URL":"https:\/\/doi.org\/10.3390\/cancers18010026","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,21]]}}}